Faculty: María-Victoria Mateos, MD, PhD

This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-world implementation. Together, these insights help clinicians optimize patient outcomes as bispecific antibodies move toward earlier integration in multiple myeloma care.

On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.